![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SCG3 |
Gene summary for SCG3 |
![]() |
Gene information | Species | Human | Gene symbol | SCG3 | Gene ID | 29106 |
Gene name | secretogranin III | |
Gene Alias | SGIII | |
Cytomap | 15q21.2 | |
Gene Type | protein-coding | GO ID | GO:0008104 | UniProtAcc | Q8WXD2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
29106 | SCG3 | S014 | Human | Liver | HCC | 3.91e-17 | 8.50e-01 | 0.2254 |
29106 | SCG3 | S015 | Human | Liver | HCC | 5.98e-31 | 2.19e+00 | 0.2375 |
29106 | SCG3 | S016 | Human | Liver | HCC | 3.86e-45 | 1.59e+00 | 0.2243 |
29106 | SCG3 | HTA12-15-2 | Human | Pancreas | PDAC | 3.78e-09 | 6.52e-01 | 0.2315 |
29106 | SCG3 | HTA12-23-1 | Human | Pancreas | PDAC | 2.25e-04 | 5.34e-01 | 0.3405 |
29106 | SCG3 | HTA12-26-1 | Human | Pancreas | PDAC | 4.88e-07 | 3.79e-01 | 0.3728 |
29106 | SCG3 | HTA12-29-1 | Human | Pancreas | PDAC | 1.94e-18 | 4.40e-01 | 0.3722 |
29106 | SCG3 | HTA12-9-3 | Human | Pancreas | PDAC | 8.76e-04 | 5.55e-01 | 0.2045 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SCG3 | SNV | Missense_Mutation | c.278N>T | p.Ser93Phe | p.S93F | Q8WXD2 | protein_coding | deleterious_low_confidence(0.04) | benign(0.003) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SCG3 | SNV | Missense_Mutation | c.959N>A | p.Ser320Tyr | p.S320Y | Q8WXD2 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.628) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
SCG3 | SNV | Missense_Mutation | novel | c.957N>G | p.Ile319Met | p.I319M | Q8WXD2 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.832) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SCG3 | SNV | Missense_Mutation | c.404C>T | p.Pro135Leu | p.P135L | Q8WXD2 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.982) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SCG3 | SNV | Missense_Mutation | novel | c.1292A>G | p.Tyr431Cys | p.Y431C | Q8WXD2 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.98) | TCGA-BS-A0VI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SCG3 | SNV | Missense_Mutation | novel | c.451N>G | p.Ile151Val | p.I151V | Q8WXD2 | protein_coding | deleterious_low_confidence(0.01) | benign(0.203) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
SCG3 | SNV | Missense_Mutation | novel | c.707N>G | p.Ile236Ser | p.I236S | Q8WXD2 | protein_coding | tolerated_low_confidence(0.41) | benign(0.036) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
SCG3 | SNV | Missense_Mutation | novel | c.860N>G | p.Ile287Ser | p.I287S | Q8WXD2 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.898) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SCG3 | SNV | Missense_Mutation | novel | c.1117N>T | p.Ala373Ser | p.A373S | Q8WXD2 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.997) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SCG3 | SNV | Missense_Mutation | novel | c.689N>C | p.Val230Ala | p.V230A | Q8WXD2 | protein_coding | tolerated_low_confidence(0.76) | benign(0.003) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |